Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
In patients previously treated with covalent, irreversible BTK inhibitors, pirtobrutinib (a noncovalent, reversible BTK inhibitor) induced responses in 73%, with a median progression-free survival of nearly 20 months.
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2023-07, Vol.389 (1), p.33-44 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 44 |
|---|---|
| container_issue | 1 |
| container_start_page | 33 |
| container_title | The New England journal of medicine |
| container_volume | 389 |
| creator | Mato, Anthony R. Woyach, Jennifer A. Brown, Jennifer R. Ghia, Paolo Patel, Krish Eyre, Toby A. Munir, Talha Lech-Maranda, Ewa Lamanna, Nicole Tam, Constantine S. Shah, Nirav N. Coombs, Catherine C. Ujjani, Chaitra S. Fakhri, Bita Cheah, Chan Y. Patel, Manish R. Alencar, Alvaro J. Cohen, Jonathon B. Gerson, James N. Flinn, Ian W. Ma, Shuo Jagadeesh, Deepa Rhodes, Joanna M. Hernandez-Ilizaliturri, Francisco Zinzani, Pier L. Seymour, John F. Balbas, Minna Nair, Binoj Abada, Paolo Wang, Chunxiao Ruppert, Amy S. Wang, Denise Tsai, Donald E. Wierda, William G. Jurczak, Wojciech |
| description | In patients previously treated with covalent, irreversible BTK inhibitors, pirtobrutinib (a noncovalent, reversible BTK inhibitor) induced responses in 73%, with a median progression-free survival of nearly 20 months. |
| doi_str_mv | 10.1056/NEJMoa2300696 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2833999465</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2833999465</sourcerecordid><originalsourceid>FETCH-LOGICAL-c351t-9477a4541e2c36c4f95d95112f6078cabf140ebff47ffcfa4ed1a89b8730e71d3</originalsourceid><addsrcrecordid>eNp10M1LwzAYBvAgipvTo1cpiOClmjRp0hy1TJ3Wj8M8lzRNWObazCQV9t_buSkomMubF348vDwAHCN4gWBKL5_G949WJBhCyukOGKIU45gQSHfBEMIkiwnjeAAOvJ_D_iHC98EAMwJZvwxB8WJcsJXrgmlNFQkdlItElNsPsVBtiK6nD9GknZnKBOsi00b5zNnWyKhYNcuZlauw_qvuTTVGHII9LRZeHW3nCLzejKf5XVw8307yqyKWOEUh5oQxQVKCVCIxlUTztOYpQommkGVSVBoRqCqtCdNaakFUjUTGq4xhqBiq8Qicb3KXzr53yoeyMV6qxUK0yna-TDKMOeeEpj09_UPntnNtf92XollCKOxVvFHSWe-d0uXSmUa4VYlgua65_FVz70-2qV3VqPpHf_fag7MNaBpftmre_BP0CXffgmc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2833682460</pqid></control><display><type>article</type><title>Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>New England Journal of Medicine</source><creator>Mato, Anthony R. ; Woyach, Jennifer A. ; Brown, Jennifer R. ; Ghia, Paolo ; Patel, Krish ; Eyre, Toby A. ; Munir, Talha ; Lech-Maranda, Ewa ; Lamanna, Nicole ; Tam, Constantine S. ; Shah, Nirav N. ; Coombs, Catherine C. ; Ujjani, Chaitra S. ; Fakhri, Bita ; Cheah, Chan Y. ; Patel, Manish R. ; Alencar, Alvaro J. ; Cohen, Jonathon B. ; Gerson, James N. ; Flinn, Ian W. ; Ma, Shuo ; Jagadeesh, Deepa ; Rhodes, Joanna M. ; Hernandez-Ilizaliturri, Francisco ; Zinzani, Pier L. ; Seymour, John F. ; Balbas, Minna ; Nair, Binoj ; Abada, Paolo ; Wang, Chunxiao ; Ruppert, Amy S. ; Wang, Denise ; Tsai, Donald E. ; Wierda, William G. ; Jurczak, Wojciech</creator><creatorcontrib>Mato, Anthony R. ; Woyach, Jennifer A. ; Brown, Jennifer R. ; Ghia, Paolo ; Patel, Krish ; Eyre, Toby A. ; Munir, Talha ; Lech-Maranda, Ewa ; Lamanna, Nicole ; Tam, Constantine S. ; Shah, Nirav N. ; Coombs, Catherine C. ; Ujjani, Chaitra S. ; Fakhri, Bita ; Cheah, Chan Y. ; Patel, Manish R. ; Alencar, Alvaro J. ; Cohen, Jonathon B. ; Gerson, James N. ; Flinn, Ian W. ; Ma, Shuo ; Jagadeesh, Deepa ; Rhodes, Joanna M. ; Hernandez-Ilizaliturri, Francisco ; Zinzani, Pier L. ; Seymour, John F. ; Balbas, Minna ; Nair, Binoj ; Abada, Paolo ; Wang, Chunxiao ; Ruppert, Amy S. ; Wang, Denise ; Tsai, Donald E. ; Wierda, William G. ; Jurczak, Wojciech</creatorcontrib><description>In patients previously treated with covalent, irreversible BTK inhibitors, pirtobrutinib (a noncovalent, reversible BTK inhibitor) induced responses in 73%, with a median progression-free survival of nearly 20 months.</description><identifier>ISSN: 0028-4793</identifier><identifier>ISSN: 1533-4406</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa2300696</identifier><identifier>PMID: 37407001</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Adverse events ; Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors ; Anticoagulants ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; B-cell lymphoma ; Bleeding ; Bruton's tyrosine kinase ; Cancer ; Chronic lymphocytic leukemia ; Confidence intervals ; Disease ; Drug dosages ; Enrollments ; FDA approval ; Hematology ; Hemorrhage ; Hemorrhage - chemically induced ; Humans ; Kinases ; Leukemia ; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy ; Lymphocytes B ; Lymphocytosis ; Lymphoma ; Neutropenia ; Neutropenia - chemically induced ; Oncology ; Patients ; Progression-Free Survival ; Protein Kinase Inhibitors - administration & dosage ; Protein Kinase Inhibitors - adverse effects ; Protein Kinase Inhibitors - therapeutic use ; Protein-tyrosine kinase ; Statistical analysis ; Treatments in Oncology</subject><ispartof>The New England journal of medicine, 2023-07, Vol.389 (1), p.33-44</ispartof><rights>Copyright © 2023 Massachusetts Medical Society. All rights reserved.</rights><rights>Copyright © 2023 Massachusetts Medical Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c351t-9477a4541e2c36c4f95d95112f6078cabf140ebff47ffcfa4ed1a89b8730e71d3</citedby><cites>FETCH-LOGICAL-c351t-9477a4541e2c36c4f95d95112f6078cabf140ebff47ffcfa4ed1a89b8730e71d3</cites><orcidid>0000-0002-2446-098X ; 0000-0001-7988-1565 ; 0000-0003-2188-6835 ; 0000-0002-4336-1071 ; 0000-0003-2040-4961 ; 0000-0002-1720-9295</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa2300696$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa2300696$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37407001$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mato, Anthony R.</creatorcontrib><creatorcontrib>Woyach, Jennifer A.</creatorcontrib><creatorcontrib>Brown, Jennifer R.</creatorcontrib><creatorcontrib>Ghia, Paolo</creatorcontrib><creatorcontrib>Patel, Krish</creatorcontrib><creatorcontrib>Eyre, Toby A.</creatorcontrib><creatorcontrib>Munir, Talha</creatorcontrib><creatorcontrib>Lech-Maranda, Ewa</creatorcontrib><creatorcontrib>Lamanna, Nicole</creatorcontrib><creatorcontrib>Tam, Constantine S.</creatorcontrib><creatorcontrib>Shah, Nirav N.</creatorcontrib><creatorcontrib>Coombs, Catherine C.</creatorcontrib><creatorcontrib>Ujjani, Chaitra S.</creatorcontrib><creatorcontrib>Fakhri, Bita</creatorcontrib><creatorcontrib>Cheah, Chan Y.</creatorcontrib><creatorcontrib>Patel, Manish R.</creatorcontrib><creatorcontrib>Alencar, Alvaro J.</creatorcontrib><creatorcontrib>Cohen, Jonathon B.</creatorcontrib><creatorcontrib>Gerson, James N.</creatorcontrib><creatorcontrib>Flinn, Ian W.</creatorcontrib><creatorcontrib>Ma, Shuo</creatorcontrib><creatorcontrib>Jagadeesh, Deepa</creatorcontrib><creatorcontrib>Rhodes, Joanna M.</creatorcontrib><creatorcontrib>Hernandez-Ilizaliturri, Francisco</creatorcontrib><creatorcontrib>Zinzani, Pier L.</creatorcontrib><creatorcontrib>Seymour, John F.</creatorcontrib><creatorcontrib>Balbas, Minna</creatorcontrib><creatorcontrib>Nair, Binoj</creatorcontrib><creatorcontrib>Abada, Paolo</creatorcontrib><creatorcontrib>Wang, Chunxiao</creatorcontrib><creatorcontrib>Ruppert, Amy S.</creatorcontrib><creatorcontrib>Wang, Denise</creatorcontrib><creatorcontrib>Tsai, Donald E.</creatorcontrib><creatorcontrib>Wierda, William G.</creatorcontrib><creatorcontrib>Jurczak, Wojciech</creatorcontrib><title>Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>In patients previously treated with covalent, irreversible BTK inhibitors, pirtobrutinib (a noncovalent, reversible BTK inhibitor) induced responses in 73%, with a median progression-free survival of nearly 20 months.</description><subject>Adverse events</subject><subject>Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors</subject><subject>Anticoagulants</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>B-cell lymphoma</subject><subject>Bleeding</subject><subject>Bruton's tyrosine kinase</subject><subject>Cancer</subject><subject>Chronic lymphocytic leukemia</subject><subject>Confidence intervals</subject><subject>Disease</subject><subject>Drug dosages</subject><subject>Enrollments</subject><subject>FDA approval</subject><subject>Hematology</subject><subject>Hemorrhage</subject><subject>Hemorrhage - chemically induced</subject><subject>Humans</subject><subject>Kinases</subject><subject>Leukemia</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</subject><subject>Lymphocytes B</subject><subject>Lymphocytosis</subject><subject>Lymphoma</subject><subject>Neutropenia</subject><subject>Neutropenia - chemically induced</subject><subject>Oncology</subject><subject>Patients</subject><subject>Progression-Free Survival</subject><subject>Protein Kinase Inhibitors - administration & dosage</subject><subject>Protein Kinase Inhibitors - adverse effects</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Protein-tyrosine kinase</subject><subject>Statistical analysis</subject><subject>Treatments in Oncology</subject><issn>0028-4793</issn><issn>1533-4406</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp10M1LwzAYBvAgipvTo1cpiOClmjRp0hy1TJ3Wj8M8lzRNWObazCQV9t_buSkomMubF348vDwAHCN4gWBKL5_G949WJBhCyukOGKIU45gQSHfBEMIkiwnjeAAOvJ_D_iHC98EAMwJZvwxB8WJcsJXrgmlNFQkdlItElNsPsVBtiK6nD9GknZnKBOsi00b5zNnWyKhYNcuZlauw_qvuTTVGHII9LRZeHW3nCLzejKf5XVw8307yqyKWOEUh5oQxQVKCVCIxlUTztOYpQommkGVSVBoRqCqtCdNaakFUjUTGq4xhqBiq8Qicb3KXzr53yoeyMV6qxUK0yna-TDKMOeeEpj09_UPntnNtf92XollCKOxVvFHSWe-d0uXSmUa4VYlgua65_FVz70-2qV3VqPpHf_fag7MNaBpftmre_BP0CXffgmc</recordid><startdate>20230706</startdate><enddate>20230706</enddate><creator>Mato, Anthony R.</creator><creator>Woyach, Jennifer A.</creator><creator>Brown, Jennifer R.</creator><creator>Ghia, Paolo</creator><creator>Patel, Krish</creator><creator>Eyre, Toby A.</creator><creator>Munir, Talha</creator><creator>Lech-Maranda, Ewa</creator><creator>Lamanna, Nicole</creator><creator>Tam, Constantine S.</creator><creator>Shah, Nirav N.</creator><creator>Coombs, Catherine C.</creator><creator>Ujjani, Chaitra S.</creator><creator>Fakhri, Bita</creator><creator>Cheah, Chan Y.</creator><creator>Patel, Manish R.</creator><creator>Alencar, Alvaro J.</creator><creator>Cohen, Jonathon B.</creator><creator>Gerson, James N.</creator><creator>Flinn, Ian W.</creator><creator>Ma, Shuo</creator><creator>Jagadeesh, Deepa</creator><creator>Rhodes, Joanna M.</creator><creator>Hernandez-Ilizaliturri, Francisco</creator><creator>Zinzani, Pier L.</creator><creator>Seymour, John F.</creator><creator>Balbas, Minna</creator><creator>Nair, Binoj</creator><creator>Abada, Paolo</creator><creator>Wang, Chunxiao</creator><creator>Ruppert, Amy S.</creator><creator>Wang, Denise</creator><creator>Tsai, Donald E.</creator><creator>Wierda, William G.</creator><creator>Jurczak, Wojciech</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2446-098X</orcidid><orcidid>https://orcid.org/0000-0001-7988-1565</orcidid><orcidid>https://orcid.org/0000-0003-2188-6835</orcidid><orcidid>https://orcid.org/0000-0002-4336-1071</orcidid><orcidid>https://orcid.org/0000-0003-2040-4961</orcidid><orcidid>https://orcid.org/0000-0002-1720-9295</orcidid></search><sort><creationdate>20230706</creationdate><title>Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia</title><author>Mato, Anthony R. ; Woyach, Jennifer A. ; Brown, Jennifer R. ; Ghia, Paolo ; Patel, Krish ; Eyre, Toby A. ; Munir, Talha ; Lech-Maranda, Ewa ; Lamanna, Nicole ; Tam, Constantine S. ; Shah, Nirav N. ; Coombs, Catherine C. ; Ujjani, Chaitra S. ; Fakhri, Bita ; Cheah, Chan Y. ; Patel, Manish R. ; Alencar, Alvaro J. ; Cohen, Jonathon B. ; Gerson, James N. ; Flinn, Ian W. ; Ma, Shuo ; Jagadeesh, Deepa ; Rhodes, Joanna M. ; Hernandez-Ilizaliturri, Francisco ; Zinzani, Pier L. ; Seymour, John F. ; Balbas, Minna ; Nair, Binoj ; Abada, Paolo ; Wang, Chunxiao ; Ruppert, Amy S. ; Wang, Denise ; Tsai, Donald E. ; Wierda, William G. ; Jurczak, Wojciech</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c351t-9477a4541e2c36c4f95d95112f6078cabf140ebff47ffcfa4ed1a89b8730e71d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adverse events</topic><topic>Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors</topic><topic>Anticoagulants</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>B-cell lymphoma</topic><topic>Bleeding</topic><topic>Bruton's tyrosine kinase</topic><topic>Cancer</topic><topic>Chronic lymphocytic leukemia</topic><topic>Confidence intervals</topic><topic>Disease</topic><topic>Drug dosages</topic><topic>Enrollments</topic><topic>FDA approval</topic><topic>Hematology</topic><topic>Hemorrhage</topic><topic>Hemorrhage - chemically induced</topic><topic>Humans</topic><topic>Kinases</topic><topic>Leukemia</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</topic><topic>Lymphocytes B</topic><topic>Lymphocytosis</topic><topic>Lymphoma</topic><topic>Neutropenia</topic><topic>Neutropenia - chemically induced</topic><topic>Oncology</topic><topic>Patients</topic><topic>Progression-Free Survival</topic><topic>Protein Kinase Inhibitors - administration & dosage</topic><topic>Protein Kinase Inhibitors - adverse effects</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Protein-tyrosine kinase</topic><topic>Statistical analysis</topic><topic>Treatments in Oncology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mato, Anthony R.</creatorcontrib><creatorcontrib>Woyach, Jennifer A.</creatorcontrib><creatorcontrib>Brown, Jennifer R.</creatorcontrib><creatorcontrib>Ghia, Paolo</creatorcontrib><creatorcontrib>Patel, Krish</creatorcontrib><creatorcontrib>Eyre, Toby A.</creatorcontrib><creatorcontrib>Munir, Talha</creatorcontrib><creatorcontrib>Lech-Maranda, Ewa</creatorcontrib><creatorcontrib>Lamanna, Nicole</creatorcontrib><creatorcontrib>Tam, Constantine S.</creatorcontrib><creatorcontrib>Shah, Nirav N.</creatorcontrib><creatorcontrib>Coombs, Catherine C.</creatorcontrib><creatorcontrib>Ujjani, Chaitra S.</creatorcontrib><creatorcontrib>Fakhri, Bita</creatorcontrib><creatorcontrib>Cheah, Chan Y.</creatorcontrib><creatorcontrib>Patel, Manish R.</creatorcontrib><creatorcontrib>Alencar, Alvaro J.</creatorcontrib><creatorcontrib>Cohen, Jonathon B.</creatorcontrib><creatorcontrib>Gerson, James N.</creatorcontrib><creatorcontrib>Flinn, Ian W.</creatorcontrib><creatorcontrib>Ma, Shuo</creatorcontrib><creatorcontrib>Jagadeesh, Deepa</creatorcontrib><creatorcontrib>Rhodes, Joanna M.</creatorcontrib><creatorcontrib>Hernandez-Ilizaliturri, Francisco</creatorcontrib><creatorcontrib>Zinzani, Pier L.</creatorcontrib><creatorcontrib>Seymour, John F.</creatorcontrib><creatorcontrib>Balbas, Minna</creatorcontrib><creatorcontrib>Nair, Binoj</creatorcontrib><creatorcontrib>Abada, Paolo</creatorcontrib><creatorcontrib>Wang, Chunxiao</creatorcontrib><creatorcontrib>Ruppert, Amy S.</creatorcontrib><creatorcontrib>Wang, Denise</creatorcontrib><creatorcontrib>Tsai, Donald E.</creatorcontrib><creatorcontrib>Wierda, William G.</creatorcontrib><creatorcontrib>Jurczak, Wojciech</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mato, Anthony R.</au><au>Woyach, Jennifer A.</au><au>Brown, Jennifer R.</au><au>Ghia, Paolo</au><au>Patel, Krish</au><au>Eyre, Toby A.</au><au>Munir, Talha</au><au>Lech-Maranda, Ewa</au><au>Lamanna, Nicole</au><au>Tam, Constantine S.</au><au>Shah, Nirav N.</au><au>Coombs, Catherine C.</au><au>Ujjani, Chaitra S.</au><au>Fakhri, Bita</au><au>Cheah, Chan Y.</au><au>Patel, Manish R.</au><au>Alencar, Alvaro J.</au><au>Cohen, Jonathon B.</au><au>Gerson, James N.</au><au>Flinn, Ian W.</au><au>Ma, Shuo</au><au>Jagadeesh, Deepa</au><au>Rhodes, Joanna M.</au><au>Hernandez-Ilizaliturri, Francisco</au><au>Zinzani, Pier L.</au><au>Seymour, John F.</au><au>Balbas, Minna</au><au>Nair, Binoj</au><au>Abada, Paolo</au><au>Wang, Chunxiao</au><au>Ruppert, Amy S.</au><au>Wang, Denise</au><au>Tsai, Donald E.</au><au>Wierda, William G.</au><au>Jurczak, Wojciech</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2023-07-06</date><risdate>2023</risdate><volume>389</volume><issue>1</issue><spage>33</spage><epage>44</epage><pages>33-44</pages><issn>0028-4793</issn><issn>1533-4406</issn><eissn>1533-4406</eissn><abstract>In patients previously treated with covalent, irreversible BTK inhibitors, pirtobrutinib (a noncovalent, reversible BTK inhibitor) induced responses in 73%, with a median progression-free survival of nearly 20 months.</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>37407001</pmid><doi>10.1056/NEJMoa2300696</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-2446-098X</orcidid><orcidid>https://orcid.org/0000-0001-7988-1565</orcidid><orcidid>https://orcid.org/0000-0003-2188-6835</orcidid><orcidid>https://orcid.org/0000-0002-4336-1071</orcidid><orcidid>https://orcid.org/0000-0003-2040-4961</orcidid><orcidid>https://orcid.org/0000-0002-1720-9295</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2023-07, Vol.389 (1), p.33-44 |
| issn | 0028-4793 1533-4406 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2833999465 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; New England Journal of Medicine |
| subjects | Adverse events Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors Anticoagulants Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use B-cell lymphoma Bleeding Bruton's tyrosine kinase Cancer Chronic lymphocytic leukemia Confidence intervals Disease Drug dosages Enrollments FDA approval Hematology Hemorrhage Hemorrhage - chemically induced Humans Kinases Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Lymphocytes B Lymphocytosis Lymphoma Neutropenia Neutropenia - chemically induced Oncology Patients Progression-Free Survival Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Protein-tyrosine kinase Statistical analysis Treatments in Oncology |
| title | Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T03%3A43%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pirtobrutinib%20after%20a%20Covalent%20BTK%20Inhibitor%20in%20Chronic%20Lymphocytic%20Leukemia&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Mato,%20Anthony%20R.&rft.date=2023-07-06&rft.volume=389&rft.issue=1&rft.spage=33&rft.epage=44&rft.pages=33-44&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMoa2300696&rft_dat=%3Cproquest_cross%3E2833999465%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2833682460&rft_id=info:pmid/37407001&rfr_iscdi=true |